Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2023 | Percentile | Sector n |
|---|---|---|---|---|
| CIS Pharma | Pharma | 47.4% | 97th pct | 123 |
| Mermisi | Pharma | 30.7% | 75th pct | 123 |
| Gea | Pharma | 27.8% | 69th pct | 123 |
| Welfare International | Pharma | 21.3% | 57th pct | 123 |
| Ivermedi | Pharma | 6.6% | 28th pct | 123 |
Percentile is within each company's own sector across the whole FY2023 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2023 | CIS Pharma | Ivermedi | Mermisi | Gea | Welfare International |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 59.8% | 23.4% | 38.1% | 48.5% | 33.1% |
| EBITDA Margin | 47.4% | 6.6% | 30.7% | 27.8% | 21.3% |
| EBITDAR | 23,115 | 3,129 | 13,876 | 12,469 | 6,337 |
| EBITDAR Margin | 47.9% | 6.6% | 30.7% | 27.8% | 21.3% |
| EBIT Margin | 47.2% | 6.6% | 29.9% | 27.2% | 21.3% |
| Net Profit Margin | 46.2% | 9.3% | 27.1% | 32.4% | 14.6% |
| Operating Expense % of Sales | 12.4% | 16.8% | 7.4% | 20.7% | 11.8% |
| Returns | |||||
| Return on Assets (ROA) | 70.1% | 10.3% | 30.1% | 37.9% | 18.8% |
| Return on Equity (ROE) | 121.1% | 12.3% | 35.7% | 50.2% | 46.7% |
| ROIC [EBIT / Invested Capital] | 121.7% | ||||
| 11.9% |
| 52.8% |
| 44.7% |
| 68.4% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 1.3% | 0.1% | 9.9% | 2.8% | 0.0% |
| Debt-to-Equity | 0.02x | 0.00x | 0.12x | 0.04x | 0.00x |
| Debt-to-EBITDA | 0.02x | 0.01x | 0.29x | 0.09x | 0.00x |
| Equity-to-Assets | 57.9% | 84.1% | 84.4% | 75.4% | 40.2% |
| Net Debt | 321 | -9,424 | -8,763 | -1,701 | -5 |
| Cash & Equivalents | 99 | 9,464 | 12,797 | 2,794 | 5 |
| Total Debt | 420 | 40 | 4,034 | 1,092 | N/A |
| Liquidity & working capital | |||||
| Current Ratio | 2.22x | 4.07x | 5.64x | 3.39x | 3.05x |
| Quick Ratio | 1.96x | 3.61x | 5.64x | 2.27x | 2.54x |
| Cash Ratio | 0.01x | 1.41x | 2.01x | 0.32x | 0.00x |
| Total Current Assets | 29,667 | 27,245 | 35,912 | 29,747 | 41,874 |
| Total Current Liabilities | 13,379 | 6,700 | 6,368 | 8,764 | 13,748 |
| Inventory | 3,469 | 3,078 | N/A | 9,821 | 6,909 |
| Trade Receivables | 26,098 | 13,381 | 15,972 | 16,344 | 16,048 |
| Trade Payables | 12,959 | 6,700 | 2,301 | 4,469 | 11,097 |
| Net Working Capital | 16,288 | 20,545 | 29,544 | 20,982 | 28,126 |
| Net Working Capital % of Revenue | 33.8% | 43.6% | 65.5% | 46.8% | 94.7% |
| Trade Working Capital | 16,608 | 9,759 | 13,671 | 21,697 | 11,860 |
| Trade Working Capital % of Revenue | 34.4% | 20.7% | 30.3% | 48.4% | 39.9% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | 5.58x | 11.73x | N/A | 2.35x | 2.87x |
| Days Inventory Outstanding (DIO) | 65.4 | 31.1 | N/A | 155.3 | 127.0 |
| Receivables Turnover | 1.85x | 3.52x | 2.83x | 2.74x | 1.85x |
| Days Sales Outstanding (DSO) | 197.5 | 103.6 | 129.2 | 133.1 | 197.3 |
| Payables Turnover | 1.50x | 5.39x | 12.14x | 5.16x | 1.79x |
| Days Payable Outstanding (DPO) | 244.1 | 67.8 | 30.1 | 70.7 | 204.0 |
| Cash Conversion Cycle | 18.7 days | 67.0 days | 99.1 days | 217.8 days | 120.3 days |
| Asset Turnover | 1.52x | 1.11x | 1.11x | 1.17x | 1.29x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 13,265 | 1,837 | 10,166 | 9,424 | 17,039 |
| Free Cash Flow (OCF − Capex proxy) | 12,002 | 954 | 9,750 | 8,903 | 17,039 |
| Cash Conversion (OCF / EBITDA) | 58.0% | 58.7% | 73.3% | 75.6% | 268.9% |
| Dividends Declared | 12,609 | 2,749 | 6,075 | 8,500 | 17,641 |
| Dividend Payout Ratio | 56.6% | 62.7% | 49.6% | 58.5% | 408.3% |